New TAU study tracks coronavirus spread patterns in Israel

Written on |

Research finds approximately 70% of the infections in Israel were caused by a SARS-CoV2 strain imported from the United States

A  team of Tel Aviv University researchers led by Dr. Adi Stern of the School of Molecular Cell Biology and Biotechnology at TAU’s George S. Wise Faculty of Life Sciences have conducted the first large-scale genomic sequencing of the novel coronavirus strain that has infected to date over 16,500 people in Israel. The scientists harnessed their genomic map to pinpoint mutations indicating where the virus originated from and later spread to within Israel. The study is based on an analysis of the genomic sequences of over 200 patients at hospitals across Israel, who together constitute a representative sample of the general population. TAU doctoral students Daniel Miller, Noam Harel, Talia Kostin, Omer Tirosh and Moran Meir conducted the research for the study in collaboration with scientists at Emory University, Gertner Institute, Chaim Sheba Medical Center, the Holon Institute of Technology, Assuta Hospital Ashdod, Hadassah Ein Karem Medical Center, Soroka Medical Center, Barzilai Medical Center, Poriya Medical Center, and the Genome Center at the Technion Institute of Technology.

The origins of coronavirus

“The novel coronavirus is characterized by mutations that occur at a set pace,” explains Dr. Stern. “These mutations do not affect the virus, i.e. it remains stable, but these mutations can help us trace the chain of infection from country to country. After the pandemic broke out in Wuhan, for example, one or two mutations occurred, and one virus with a mutation may have migrated to Europe where it experienced additional mutations, and from there it traveled to the United States, and so on. “We can look at these mutations as a kind of barcode that helps us keep track of the progression and transformation of the coronavirus as it moves from country to country.” To obtain a clear picture of the origin of infection in Israel, the researchers compared the genomic sequences of local patients to some 4,700 genomic sequences taken from patients around the world. They found that more than 70% of the patients had been infected by a coronavirus strain that originated in the U.S. The remaining nearly 30% of infections were imported from Europe and elsewhere: Belgium (8%), France (6%), England (5%), Spain (3%), Italy (2%), the Philippines (2%), Australia (2%) and Russia (2%). According to Dr. Stern, the new genomic map provides insight into the precise spread of the novel coronavirus within Israel. Until now, any assessment of the spread of infection relied on such subjective parameters as patient feedback. The new research will be able to expose the rate of infection in a household, in an apartment building, in a school, in a neighborhood, and more. It will also provide early detection of super spreaders – people who travel far and wide and infect a large number of people – and could even identify major events with the potential to trigger widespread infection.

The importance of 10%

“Going forward, the data obtained from genomic sequencing will serve as an important basis for informed decisions about which institutions to close, for what amount of time, and in which format,” says Dr. Stern. With policymakers in mind, the researchers developed a complex statistical model based on genomic sequencing that estimates the epidemiological parameters of viral spread. The model shows that the rate of infection decreased significantly following strict quarantine measures taken in Israel and highlights a major discrepancy between the number of people each coronavirus patient infected. The model also estimates that over 80% of coronavirus cases in Israel were the direct result of only 10% of the coronavirus patients in Israel, meaning that these 10% were, in fact, super-spreaders. According to the model and to the genomic sequencing, Dr. Stern says that no more than 1% of the population in Israel contracted the virus – a far cry from herd immunity. “In our study, we performed the first massive genomic sequencing of the coronavirus in Israel,” she concludes. “This technology and the information it provides is of great importance for understanding the virus and its spread in the population, as a scientific and objective basis for local and national decision-making. The data obtained from the research can greatly help policymakers on issues such as closures and quarantines. In doing so, the study makes a significant contribution to dealing with the epidemic in Israel, and, more importantly: We have developed tools that will allow us to cope, in real time, with the next outbreak that may occur.”

Related posts

TAU Researchers Invent Healthy Weapon Against Covid

15 April 2022

As Pandemic Persists, TAU Forges Ahead with COVID-19 Research on All Fronts

30 December 2021

Seaweed – A Promising Defense Against Covid-19

16 December 2021

TAU Experts on Omicron: “Don’t Panic”

7 December 2021

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

8 November 2021

From Law and Education to Nursing

3 November 2021

COVID-19 Immunity Varies Among Genders and Age Groups

25 July 2021

New study found differences between women and men in the level of COVID-19 antibodies

16 July 2021

How Will We Brave the Post-COVID Era?

1 June 2021

British Variant 45% More Contagious than Original Virus

29 April 2021

COVID-19 Vaccinations at TAU

25 March 2021

Covid-19 Vaccination of Nursing Mothers May Protect Babies

25 March 2021

Academic First Responders

14 January 2021

TAU Study Proves that Light Can Kill Coronavirus

15 December 2020

COVID-19 Takes TAU’s Legal Clinics into High Gear

7 December 2020

Study: Women Suffer More from COVID-related Orofacial Pain

13 November 2020

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

P.O. Box 4044, Maroubra South,
NSW 2035
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com